Allergy Asthma and Clinical Immunology最新文献

{"title":"Anti-IL-5 and anti-IL-5 receptor therapy significantly improves quality of life and FEV1 values in patients with severe asthma.","authors":"Anaiza Odalis Villalobos Alfaro, Haydee Carolina Gutiérrez Vargas, Juan Manuel Díaz, Jonathan Alvarez Pinto, Diana Cristina García Cambero, Eduardo Hernandez Cuellar, Julio Augusto Palma Zapata, Alondra Esthefanía Llamas Domínguez, Juliana Palma Zapata, Silvia Denise Ponce-Campos","doi":"10.1186/s13223-025-00979-y","DOIUrl":"10.1186/s13223-025-00979-y","url":null,"abstract":"<p><p>In recent years, the use of monoclonal antibodies directed against interleukin-5 (anti-IL-5) and its receptor alpha (anti-IL-5R) has proven to be an effective therapeutic option for patients with severe asthma by reducing the number of eosinophils, which may promote disease remission. This study aimed to evaluate clinical improvement and remission in patients with severe asthma treated with anti-IL-5 and anti-IL-5R antibodies over a period of 12 months. A cohort study was conducted with 49 patients diagnosed with severe eosinophilic asthma and who did not respond to conventional treatment. During follow-up, medical control was performed every 3 months using spirometry, eosinophil counts, quality of life scales, and disease control. The results revealed an improvement in FEV1 after 3 months of treatment, with statistical significance at 12 months in patients treated with anti-IL-5 and at 9 months in those treated with anti-IL-5R. In addition, better perceptions of asthma control and quality of life were observed, with significant differences at 6 and 12 months. Correlations between spirometry and ACT, ACQ, and AQLQ reflect a progressive recovery of well-being and function. Finally, the remission rate was 41.1% with anti-IL-5 treatment and 47.3% with anti-IL-5R treatment after one year of follow-up. These findings support the efficacy of anti-IL-5 and anti-IL-5R treatment in improving severe asthma control and patients' quality of life, suggesting their key role in disease remission.</p>","PeriodicalId":51302,"journal":{"name":"Allergy Asthma and Clinical Immunology","volume":"21 1","pages":"34"},"PeriodicalIF":2.4,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12351985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144849575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical validation of controlled exposure to cat dander in the Specialized Particulate Control Environmental Exposure Unit (SPaC-EEU).","authors":"Lubnaa Hossenbaccus, Sophia Linton, Sarah Garvey, Hannah Botting, Terry Walker, Lisa Steacy, Anne K Ellis","doi":"10.1186/s13223-025-00978-z","DOIUrl":"10.1186/s13223-025-00978-z","url":null,"abstract":"<p><strong>Background: </strong>Cat allergen is the second most common cause of perennial allergic rhinitis. Despite its prevalence (~ 20% of the population), many patients continue to suffer from persistent symptoms due to constant exposure to cat allergens that reduce treatment efficacy. Modelling of the disease can improve our understanding of its onset and progression. The Specialized Particulate Control Environmental Exposure Unit (SPaC-EEU) is a controlled allergen challenge facility that has recently undergone a successful technical validation for cat dander exposure, measuring Felis domesticus 1 (Fel d 1). We then sought to perform a clinical validation with cat-allergic and non-allergic participants.</p><p><strong>Methods: </strong>This study consisted of 3 visits. Recruited participants attended a Screening visit where eligibility was assessed, and a skin prick test (SPT) was completed. Successfully screened cat-allergic and non-allergic participants were invited back for the Allergen Exposure visit. They attended one of two 3-hour cat dander exposure Sessions in the SPaC-EEU, due to space limitations, with a target Fel d 1 concentration of 70 ng/m³. Fel d 1 concentrations were collected using air sampling cassettes and processed using a Fel d 1-specific ELISA. Real-time particle counts were monitored using a laser particle counter (LPC). Participants recorded symptom scores at time points from baseline up to 24 h post-onset of allergen exposure. Participants returned to the research site for a 24-hour Follow-up visit. Allergic participants completed a cat exposure and Quality of Life questionnaire.</p><p><strong>Results: </strong>Forty-six (31 cat-allergic and 15 non-allergic) participants completed this study. Allergic participants had significantly larger (p < 0.0001) SPT wheals to cat hair than non-allergic controls. Twenty-five participants attended the first Session (mean Fel d 1 = 35.7 ng/m³), and 21 participants attended the second Session (mean Fel d 1 = 102.3 ng/m³). No significant differences in symptom and safety scores were observed between Sessions, hence participants' data were pooled. Allergic participants experienced significantly elevated (p < 0.05) Total Nasal Symptom Scores and Total Rhinoconjunctivitis Symptom Scores from 15 min to 24-h post-onset of allergen exposure and significantly decreased (p < 0.05) percent change in Peak Nasal Inspiratory Flow from 1 to 3 hours, compared to non-allergic controls. Mean Quality of Life scores were different between phenotypes, unimpacted by whether or not one lived with a cat.</p><p><strong>Conclusion: </strong>The SPaC-EEU can safely produce clinically relevant nasal symptoms in only cat-allergic participants, highlighting its use for modelling cat allergen-induced allergic rhinitis.</p>","PeriodicalId":51302,"journal":{"name":"Allergy Asthma and Clinical Immunology","volume":"21 1","pages":"33"},"PeriodicalIF":2.4,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144796070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2024 CSACI Annual Scientific Meeting Book of Abstracts.","authors":"","doi":"10.1186/s13223-025-00971-6","DOIUrl":"10.1186/s13223-025-00971-6","url":null,"abstract":"","PeriodicalId":51302,"journal":{"name":"Allergy Asthma and Clinical Immunology","volume":"21 Suppl 1","pages":"32"},"PeriodicalIF":2.4,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12315273/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144762255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence trends and risk factors for allergic rhinoconjunctivitis, asthma and eczema in the UK.","authors":"Lavanya Diwakar, Anuradhaa Subramanian, Divya K Shah, Sumithra Subramaniam, Victoria S Pelly, Sheila Greenfield, David Moore, Krishnarajah Nirantharakumar","doi":"10.1186/s13223-025-00975-2","DOIUrl":"10.1186/s13223-025-00975-2","url":null,"abstract":"<p><strong>Background: </strong>Allergic rhinoconjunctivitis (ARC), asthma and eczema carry a substantial morbidity. These conditions often co-exist within the same individual and their prevalence can differ based on age, ethnicity and gender.</p><p><strong>Objectives: </strong>Using a UK primary care database, we estimated the trends in prevalence over the last decade for ARC, asthma and eczema and associated risk factors.</p><p><strong>Methods: </strong>Longitudinal cohort analysis of the health improvement (THIN) database between 1st Jan 2010 and 1st Jan 2019. Logistic regression analysis was used to explore risk factors for diagnosis of these conditions.</p><p><strong>Results: </strong>An average of 4.17 million records per year were analysed, 19.4% were children and 49.75% were male. There was an increase in prevalence of ARC, asthma and eczema amongst adults during the study period, whereas ARC and asthma prevalence amongst children has fallen. By 2018, 1:8 adults and 1:14 children had ARC; asthma was diagnosed in 1:7 adults and 1:10 children whereas eczema was diagnosed in 1:6 adults and 1:4 children respectively. There were regional discrepancies in allergy prevalence across the UK. Caucasians generally had the highest rates of asthma and lower rates of ARC compared with other ethnic groups. Having other allergies substantially increases the odds of having asthma, eczema and ARC.</p><p><strong>Conclusion: </strong>The population burden of ARC, asthma and eczema in the UK is substantial. These conditions are often associated with other allergies and can, therefore, be complex to manage. These data support calls for improvement of pathways of care for allergy patients in the UK.</p>","PeriodicalId":51302,"journal":{"name":"Allergy Asthma and Clinical Immunology","volume":"21 1","pages":"31"},"PeriodicalIF":2.6,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12232741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144585577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Online food allergy and anaphylaxis education for school personnel is effective and scalable: experience with the allergyaware e-learning portal from 2015 to 2022.","authors":"Bhanu Sharma, Stephanie Ayers, Joni Huang, Jennifer Gerdts, Susan Waserman, Anthony J Levinson","doi":"10.1186/s13223-025-00977-0","DOIUrl":"10.1186/s13223-025-00977-0","url":null,"abstract":"","PeriodicalId":51302,"journal":{"name":"Allergy Asthma and Clinical Immunology","volume":"21 1","pages":"30"},"PeriodicalIF":2.6,"publicationDate":"2025-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12232682/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sputum immunoglobulin E levels correlate with eosinophilic airway regardless of atopy.","authors":"Hyo-In Rhyou, Thi Bich Tra Cao, Quang Luu Quoc, Young-Hee Nam, Hae-Sim Park","doi":"10.1186/s13223-025-00976-1","DOIUrl":"10.1186/s13223-025-00976-1","url":null,"abstract":"<p><p>Immunoglobulin E (IgE) is a key molecule that induces mast cell activation in allergic inflammation and contributes to type 2/eosinophilic inflammation in asthmatic airways. This cross-sectional study investigated the role of local IgE in asthmatic airways according to atopy, asthma control, and eosinophilic inflammation. A total of 31 adult patients with moderate-to-severe asthma were enrolled. The study subjects were classified into (1) atopic/non-atopic, (2) controlled/partly controlled/uncontrolled asthma and (3) eosinophilic/non-eosinophilic asthma. Serum/sputum IgE and serum/urine eosinophil-derived neurotoxin (EDN) were measured. Serum IgE levels were higher in atopic asthmatics than in non-atopic asthmatics, whereas no differences were noted in sputum IgE levels. Sputum IgE levels were significantly higher in uncontrolled asthmatics than in partly controlled or controlled asthmatics, and in eosinophilic asthmatics than in non-eosinophilic asthmatics, whereas no differences were noted in serum IgE levels. Significant correlations were observed between serum EDN and serum/sputum IgE levels. The production of local IgE in asthmatic airways could contribute to type 2/eosinophilic inflammation, irrespective of atopy, resulting in poor asthma control. Strategies targeting IgE may be effective in the management of non-atopic and atopic asthma.</p>","PeriodicalId":51302,"journal":{"name":"Allergy Asthma and Clinical Immunology","volume":"21 1","pages":"29"},"PeriodicalIF":2.6,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12210544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144530943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Publisher Correction: Immunoglobulin E (IgE)-mediated food allergy.","authors":"Philippe Bégin, Susan Waserman, Jennifer L P Protudjer, Samira Jeimy, Wade Watson","doi":"10.1186/s13223-025-00974-3","DOIUrl":"10.1186/s13223-025-00974-3","url":null,"abstract":"","PeriodicalId":51302,"journal":{"name":"Allergy Asthma and Clinical Immunology","volume":"21 1","pages":"28"},"PeriodicalIF":2.6,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12199493/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144499169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of a standardized emergency department asthma care pathway on health services utilization.","authors":"Chanel Kwok, Katherine Lajkosz, Carole Madeley, Mona Jabbour, Teresa To, M Diane Lougheed","doi":"10.1186/s13223-025-00973-4","DOIUrl":"10.1186/s13223-025-00973-4","url":null,"abstract":"<p><strong>Background: </strong>An evidence-based standardized ED asthma care pathway (EDACP) was developed and implemented in Ontario, Canada.</p><p><strong>Objective: </strong>To determine the impact of EDACP implementation and access to ED asthma management resources and specialists on return ED visits.</p><p><strong>Methods: </strong>All 173 Ontario hospitals were surveyed regarding their access to community and ED asthma specialists and ED asthma management resources, including EDACP implementation date and status as of August 2017. Survey data were linked to provincial health administrative data to quantify acute health services utilization. A Poisson regression interrupted time series analysis was conducted.</p><p><strong>Results: </strong>Of the 123 hospitals responding to the survey, 44 (35.8%) had approved the EDACP. Data were analyzed for the 5 years preceding (30,028 asthma visits) and 17 months following (7,916 asthma visits) implementation, with a 3-month implementation black-out period. After controlling for auto-regressive factors, EDACP implementation was associated with a 2% reduction in the absolute rate of return ED visits within 72 h (p = 0.0124), and within 7 days (p = 0.0295) at teaching hospitals. The same effect was not seen at community hospitals. Peak expiratory flow testing (available at 77% of sites) and spirometry (available at 45% of sites) were associated with 34% (p = 0.0071) and 23% (p = 0.028) reductions in the odds of return ED visits within 72 h, respectively.</p><p><strong>Conclusion: </strong>The positive results from this large-scale effort to implement an evidence-based knowledge translation initiative in diverse settings, suggests there is merit in continuing to invest time and resources to overcome barriers to adoption and implementation of this EDACP.</p>","PeriodicalId":51302,"journal":{"name":"Allergy Asthma and Clinical Immunology","volume":"21 1","pages":"27"},"PeriodicalIF":2.6,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12153106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge assessment tools in atopic dermatitis patient education: a scoping review.","authors":"Jasmin Khela, Bethany Wilken, Yuka Asai","doi":"10.1186/s13223-025-00970-7","DOIUrl":"10.1186/s13223-025-00970-7","url":null,"abstract":"<p><strong>Background: </strong>Atopic dermatitis (AD) is a chronic and inflammatory skin disease which requires continuous self-management by patients and caregivers. Patient education in AD can improve the self-management practices, treatment adherence rates, and clinical outcomes of patients. Patient-reported outcome measures and objective clinical outcome measures have been used to assess the effectiveness of AD patient education interventions, however they have limited use in assessing learning outcomes, such as knowledge. The literature on knowledge outcome measures for AD patient education interventions has not been examined to date. MAIN: We performed a scoping review of the literature on knowledge assessment tools for AD patient education interventions following the PRISMA-ScR framework. Search databases included MEDLINE, Embase, CINAHL, Education Source, Web of Science, Grey Matters, Clinical Trials.gov, and the International Clinical Trials Registry Platform (ICTRP). Of the 3914 articles identified from the search strategy, 20 studies were eligible for data extraction and summarized by narrative synthesis. Most studies were randomised controlled trials originating in the United States, Europe, and Asia, and published in the years of 2003-2023. Researchers commonly evaluated caregivers' knowledge of AD and included assessments of clinical outcome measures. Similar methods were employed for assessing subjective knowledge across studies. Likewise, studies measuring AD patient/caregiver objective knowledge used comparable methods. Multiple-choice and true/false question formats were used in objective knowledge assessments, and Likert-type scales were common for evaluating subjective knowledge. Objective knowledge assessments consisted of more questions than subjective knowledge outcome measures. Content assessed in knowledge outcome measures was relatively consistent across studies. Delivery of subjective and objective AD knowledge assessments was by telephone, in clinic, and/or online. In pre- and post-test study designs, identical knowledge outcome measures were administered.</p><p><strong>Conclusion: </strong>This scoping review highlights the diverse components of knowledge assessment tools for AD patient education interventions. Further studies on developing and validating high-quality AD knowledge outcome measures are needed for assessing the true effects of patient education interventions on improving patient/caregiver knowledge.</p>","PeriodicalId":51302,"journal":{"name":"Allergy Asthma and Clinical Immunology","volume":"21 1","pages":"26"},"PeriodicalIF":2.6,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12102993/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors contributing to non-compliance with on-demand treatment guidelines in hereditary angioedema.","authors":"Stephen D Betschel, Jonny Peter, William Lumry, Hilary Longhurst, Constance H Katelaris, Sally van Kooten, Markus Heckmann, Neil Malloy, Julie Ulloa, Sherry Danese, Markus Magerl","doi":"10.1186/s13223-025-00969-0","DOIUrl":"10.1186/s13223-025-00969-0","url":null,"abstract":"<p><strong>Background: </strong>Hereditary angioedema (HAE) is a rare genetic disorder characterized by painful and potentially life-threatening tissue swelling due to a deficiency or dysfunction of the C1 esterase inhibitor protein. Despite the availability of comprehensive on-demand treatment guidelines, compliance to guideline recommendations remains suboptimal, resulting in persisting unmet need.</p><p><strong>Methods: </strong>This observational, online survey was conducted between September 6, 2022, and October 19, 2022 to understand the behaviors and perspectives of individuals in the US with hereditary angioedema (HAE). Participants were recruited by the US Hereditary Angioedema Association and were eligible if they were US residents with clinician-diagnosed HAE type I or II and had experienced at least one HAE attack. The survey included multiple-choice, rank-order, and scale-based responses using a 5-point Likert scale for agreement and an 11-point Likert scale for anxiety. Statistical analysis was performed using Microsoft Excel, summarizing continuous variables as means, medians, and ranges, and categorical variables as frequency distributions and percentages.</p><p><strong>Results: </strong>A total of 107 out of 155 participants completed the survey (mean age = 41 years; 80.4% female). Half of the respondents used both prophylaxis and on-demand therapy, while the other half used on-demand therapy only. Icatibant was the most commonly used on-demand treatment (78.5%). The survey revealed that 57% of respondents did not treat all HAE attacks, and only 14% treated attacks immediately. Delays in treatment were common, with a mean time to treatment of 2.4 h, and younger patients were less likely to carry on-demand treatment. Reasons for delaying treatment included the perceived severity of the attack, lack of on-demand treatment availability, and pain associated with treatment. Additionally, 32.7% of respondents experienced the return of an HAE attack after initial treatment, with those delaying treatment more likely to experience recurrence. The survey also found that delayed treatment led to more severe attacks and longer recovery times, impacting work, social activities, and overall quality of life.</p><p><strong>Conclusions: </strong>Although guidelines recommend early treatment of HAE attacks, many respondents do not treat immediately. This finding underscores the importance of incorporating open patient-physician communication to improve guideline compliance and the management of HAE.</p>","PeriodicalId":51302,"journal":{"name":"Allergy Asthma and Clinical Immunology","volume":"21 1","pages":"25"},"PeriodicalIF":2.6,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}